<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36963777</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>04</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">2053-8790</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>1</Issue><PubDate><Year>2023</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Lupus science &amp; medicine</Title><ISOAbbreviation>Lupus Sci Med</ISOAbbreviation></Journal><ArticleTitle>Safety and efficacy of belimumab in older adults with SLE: results of an integrated analysis of clinical trial data.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">e000830</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1136/lupus-2022-000830</ELocationID><Abstract><AbstractText Label="OBJECTIVE">Assess the safety and efficacy of belimumab in older adults with SLE.</AbstractText><AbstractText Label="METHODS">This post hoc integrated analysis (GSK Study 116559) included safety data from six randomised, placebo-controlled belimumab trials (BLISS-76, BLISS-52, BLISS-SC, North East Asia study, LBSL02, EMBRACE; n=4170). The BASE study provided additional safety data (n=4003). Efficacy data were from five of the trials. Older adults (&#x2265;65 years) were compared with the overall populations of patients with SLE. Patients who had received &#x2265;1 treatment dose were included.</AbstractText><AbstractText Label="RESULTS">Sixty-three older adults (1.5%) were included in the pooled safety analysis population and 156 (3.9%) in the BASE study. At baseline, older adults had lower disease activity but more organ damage than the overall populations. In the pooled safety analysis population, five (18.5%) placebo-treated and ten (27.8%) belimumab-treated older adults experienced &#x2265;1 serious adverse event (SAE), as did 230 (17.0%) placebo-treated and 421 (15.0%) belimumab-treated patients overall. In the BASE study, nine (11.0%) placebo-treated and six (8.1%) belimumab-treated older adults experienced &#x2265;1&#x2009;SAE, as did 222 (11.1%) placebo-treated and 220 (11.0%) belimumab-treated patients overall. No clinically relevant differences in deaths and adverse events of special interest were observed between older adults and the overall populations. Older adults' SLE Responder Index response rates favoured belimumab versus placebo, consistent with the overall population.</AbstractText><AbstractText Label="CONCLUSION">The safety and efficacy of belimumab in older adults were generally consistent with the overall populations, suggesting belimumab is a treatment option for older patients with SLE. Due to small numbers of older adults, findings should be interpreted with caution.</AbstractText><CopyrightInformation>&#xa9; Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>D'Cruz</LastName><ForeName>David</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-6983-8421</Identifier><AffiliationInfo><Affiliation>Louise Coote Lupus Unit, Guy's Hospital, London, UK david.d'cruz@kcl.ac.uk.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eriksson</LastName><ForeName>Gina</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Research and Development, GSK, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Green</LastName><ForeName>Yulia</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Immunology, GSK, Brentford, Middlesex, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hammer</LastName><ForeName>Anne</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Immunology Biostatistics, GSK, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ji</LastName><ForeName>Beulah</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Research and Development, GSK, Brentford, Middlesex, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meizlik</LastName><ForeName>Paige</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Global Safety, GSK, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roth</LastName><ForeName>David A</ForeName><Initials>DA</Initials><AffiliationInfo><Affiliation>Research and Development, GSK, Collegeville, Pennsylvania, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lupus Sci Med</MedlineTA><NlmUniqueID>101633705</NlmUniqueID><ISSNLinking>2053-8790</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>73B0K5S26A</RegistryNumber><NameOfSubstance UI="C511911">belimumab</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="Y">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Autoimmune Diseases</Keyword><Keyword MajorTopicYN="N">Inflammation</Keyword><Keyword MajorTopicYN="N">Lupus Erythematosus, Systemic</Keyword></KeywordList><CoiStatement>Competing interests: DD&#x2019;C worked as a consultant for GSK, UCB and Eli Lilly and was a paid speaker for GSK and Vifor Pharma. GE, YG, AH, BJ and DAR are employees of GSK and own stocks and shares in the company. PM was an employee of GSK at the time of the study and held stocks and shares in the company.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>28</Day><Hour>19</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>24</Day><Hour>20</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36963777</ArticleId><ArticleId IdType="pmc">PMC10040006</ArticleId><ArticleId IdType="doi">10.1136/lupus-2022-000830</ArticleId><ArticleId IdType="pii">10/1/e000830</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Bertoli AM, Alarc&#xf3;n GS, Calvo-Al&#xe9;n J, et al. . Systemic lupus erythematosus in a multiethnic US cohort. XXXIII. Clinical [ corrected ] features, course, and outcome in patients with late-onset disease. Arthritis Rheum 2006;54:1580&#x2013;7. 10.1002/art.21765</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.21765</ArticleId><ArticleId IdType="pubmed">16645994</ArticleId></ArticleIdList></Reference><Reference><Citation>Appenzeller S, Pereira DA, Costallat LTL. Greater accrual damage in late-onset systemic lupus erythematosus: a long-term follow-up study. Lupus 2008;17:1023&#x2013;8. 10.1177/0961203308089695</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203308089695</ArticleId><ArticleId IdType="pubmed">18852227</ArticleId></ArticleIdList></Reference><Reference><Citation>Lazaro D. Elderly-onset systemic lupus erythematosus: prevalence, clinical course and treatment. Drugs Aging 2007;24:701&#x2013;15. 10.2165/00002512-200724090-00001</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/00002512-200724090-00001</ArticleId><ArticleId IdType="pubmed">17727302</ArticleId></ArticleIdList></Reference><Reference><Citation>Furie R, Petri M, Zamani O, et al. . A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011;63:3918&#x2013;30. 10.1002/art.30613</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.30613</ArticleId><ArticleId IdType="pmc">PMC5007058</ArticleId><ArticleId IdType="pubmed">22127708</ArticleId></ArticleIdList></Reference><Reference><Citation>Navarra SV, Guzm&#xe1;n RM, Gallacher AE, et al. . Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011;377:721&#x2013;31. 10.1016/S0140-6736(10)61354-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(10)61354-2</ArticleId><ArticleId IdType="pubmed">21296403</ArticleId></ArticleIdList></Reference><Reference><Citation>Stohl W, Schwarting A, Okada M, et al. . Efficacy and safety of subcutaneous belimumab in systemic lupus erythematosus: a fifty-two-week randomized, double-blind, placebo-controlled study. Arthritis Rheumatol 2017;69:1016&#x2013;27. 10.1002/art.40049</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.40049</ArticleId><ArticleId IdType="pmc">PMC5434872</ArticleId><ArticleId IdType="pubmed">28118533</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang F, Bae S-C, Bass D, et al. . A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea. Ann Rheum Dis 2018;77:355&#x2013;63. 10.1136/annrheumdis-2017-211631</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2017-211631</ArticleId><ArticleId IdType="pmc">PMC5867402</ArticleId><ArticleId IdType="pubmed">29295825</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnaud L, Mathian A, Boddaert J, et al. . Late-Onset systemic lupus erythematosus: epidemiology, diagnosis and treatment. Drugs Aging 2012;29:181&#x2013;9. 10.2165/11598550-000000000-00000</Citation><ArticleIdList><ArticleId IdType="doi">10.2165/11598550-000000000-00000</ArticleId><ArticleId IdType="pubmed">22263748</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddaert J, Huong DLT, Amoura Z, et al. . Late-Onset systemic lupus erythematosus: a personal series of 47 patients and pooled analysis of 714 cases in the literature. Medicine (Baltimore) 2004;83:348&#x2013;59. 10.1097/01.md.0000147737.57861.7c</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.md.0000147737.57861.7c</ArticleId><ArticleId IdType="pubmed">15525847</ArticleId></ArticleIdList></Reference><Reference><Citation>Wallace DJ, Stohl W, Furie RA, et al. . A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168&#x2013;78. 10.1002/art.24699</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.24699</ArticleId><ArticleId IdType="pmc">PMC2758229</ArticleId><ArticleId IdType="pubmed">19714604</ArticleId></ArticleIdList></Reference><Reference><Citation>Ginzler E, Guedes Barbosa LS, D&#x2019;Cruz D, et al. . Phase III/IV, randomized, fifty-two-week study of the efficacy and safety of belimumab in patients of black African ancestry with systemic lupus erythematosus. Arthritis Rheumatol 2022;74:112&#x2013;23. 10.1002/art.41900</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.41900</ArticleId><ArticleId IdType="pmc">PMC9300099</ArticleId><ArticleId IdType="pubmed">34164944</ArticleId></ArticleIdList></Reference><Reference><Citation>Sheikh SZ, Scheinberg MA, Wei J-C, et al. . Mortality and adverse events of special interest with intravenous belimumab for adults with active, autoantibody-positive systemic lupus erythematosus (BASE): a multicentre, double-blind, randomised, placebo-controlled, phase 4 trial. The Lancet Rheumatology 2021;3:e122&#x2013;30. 10.1016/S2665-9913(20)30355-6</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30355-6</ArticleId></ArticleIdList></Reference><Reference><Citation>Collins CE, Cortes-Hern&#xe1;ndez J, Garcia MA, et al. . Real-world effectiveness of belimumab in the treatment of systemic lupus erythematosus: pooled analysis of multi-country data from the OBSErve studies. Rheumatol Ther 2020;7:949&#x2013;65. 10.1007/s40744-020-00243-2</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40744-020-00243-2</ArticleId><ArticleId IdType="pmc">PMC7695800</ArticleId><ArticleId IdType="pubmed">33206344</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruce IN, O&#x2019;Keeffe AG, Farewell V, et al. . Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the systemic lupus international collaborating clinics (SLICC) inception cohort. Ann Rheum Dis 2015;74:1706&#x2013;13. 10.1136/annrheumdis-2013-205171</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2013-205171</ArticleId><ArticleId IdType="pmc">PMC4552899</ArticleId><ArticleId IdType="pubmed">24834926</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;cruz D, Eriksson G, Green Y, et al. . POS0696 safety and efficacy of belimumab in older adults with systemic lupus erythematosus: results of an integrated analysis. Ann Rheum Dis 2021;80(Suppl 1):596. 10.1136/annrheumdis-2021-eular.2217</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/annrheumdis-2021-eular.2217</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>